Q9UKK9 (NUDT5_HUMAN) Homo sapiens (Human)

ADP-sugar pyrophosphatase UniProtKBInterProSTRINGInteractive Modelling

219 aa; Sequence (Fasta)

Available Structures

65 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Crystal structure of human ADP-ribose pyrophosphatase NUDT5homo-2-mer14-219
100
Crystal Structure of Human ADP-ribose Pyrophosphatase NUDT5 In complex with magnesium and AMPcprhomo-2-mer13-209
100MG;ADV;
Human NUDT5 in complex with MRK-952homo-2-mer12-208
100F2V;MG;
Crystal structure of human NUDT5 complexed with 8-oxo-dADP and manganesehomo-2-mer13-208
100MN;8DD;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;K31;EDO;CL;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;K0J;EDO;CL;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K34;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;EDO;K1P;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;K3M;EDO;CL;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K2V;EDO;
PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with FS-3764homo-2-mer14-208
100MG;EDO;PWP;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K1S;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K3Y;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;JMM;EDO;CL;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;K3V;EDO;CL;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K2M;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K0V;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K1Y;EDO;
Ground-state model of NUDT5 and corresponding apo datasets for PanDDA analysishomo-2-mer14-208
100MG;CL;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K2J;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K0M;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;K24;EDO;CL;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;K1V;EDO;CL;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;K3D;EDO;CL;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;EDO;K0S;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K3J;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K0A;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K1D;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;EDO;GQJ;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;EDO;CL;JH4;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;EDO;JJM;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K07;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;EDO;K3P;
PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with 1R-0641homo-2-mer14-208
100MG;CL;PWG;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;EDO;K1A;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K3S;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;K3A;EDO;CL;
PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with Z44592329homo-2-mer14-208
100MG;CL;K0G;EDO;
PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with GB-0804homo-2-mer14-208
100MG;CL;EDO;PW7;
PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with AE-0227homo-2-mer14-208
100MG;PWJ;EDO;CL;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;EDO;K2P;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;K1G;CL;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;EDO;K0P;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;EDO;ELQ;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K2G;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K1J;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K2S;EDO;
PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with FS-2639homo-2-mer14-208
100MG;CL;PWA;EDO;
PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with FS-1169homo-2-mer14-208
100MG;PWM;EDO;CL;
PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with SS-4432homo-2-mer14-208
100MG;CL;PWD;EDO;
PanDDA analysis group deposition -- Crystal Structure of NUDT5 in complex with 8J-537Shomo-2-mer14-208
100MG;CL;PWS;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K0D;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;K04;EDO;CL;
Crystal structure of human NUDT5homo-2-mer14-208
100MG;CL;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K41;EDO;
Crystal structure of human ADP-ribose pyrophosphatase NUDT5 in complex with magnesium and ADP-ribosehomo-2-mer14-208
100MG;APR;
Crystal Structure of Human ADP-ribose Pyrophosphatase NUDT5 In complex with Ibrutinibhomo-2-mer14-208
100.0MG;A1H14;EDO;
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…homo-2-mer14-208
100MG;CL;K0Y;EDO;
Crystal structure of human NUDT5 complexed with 8-oxo-dGDP and manganesehomo-2-mer14-208
1008GD;MN;
Potent inhibitors of NUDT5 silence hormone signaling in breast cancerhomo-2-mer14-208
100958;
Human NUDT5 with ibrutinib derivativehomo-2-mer14-208
100W0O;
Crystal structure of human NUDT5 complexed with 8-oxo-dGMPhomo-2-mer14-208
1008OG;
Crystal structure of human ADP-ribose pyrophosphatase NUDT5 in complex with magnesium and AMPhomo-2-mer14-208
100MG;AMP;
Potent inhibitors of NUDT5 silence hormone signaling in breast cancerhomo-2-mer14-208
100.09CH;

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
8ptt.1.Ahomo-2-mer0.8812-208
F2V;MG;100.00